CARDIAC · Injectable
Cardiogen.
Heart-specific cytoprotective peptide
How it works
Class & mechanism.
In short
Cardiogen is a synthetic 4-amino-acid tetrapeptide developed within the Khavinson bioregulator system, studied for its proposed cardiac cytoprotective effects — supporting cardiomyocyte survival and reducing fibrotic scarring after cardiac injury. Evidence comes primarily from preclinical rat studies and decades of Russian clinical use, with no independent Western human pharmacokinetic data or regulatory approval. It sits at Tier-C on our evidence scale: mechanistically plausible but backed by a thin, geographically limited evidence base.
Class
Cardiac Bioregulator Peptide
Mechanism
Cardiogen (Ala-Glu-Asp-Arg, AEDR) is a synthetic tetrapeptide bioregulator proposed to enter the cell nucleus and bind to DNA-associated proteins, upregulating genes responsible for cardiomyocyte survival, cytoskeletal proteins (actin, vimentin, lamin A/C), and extracellular matrix repair — per the Khavinson gene-switching model. In preclinical rat studies, it suppressed p53 protein expression in cardiac tissue, which is thought to inhibit apoptosis in stressed cardiomyocytes and promote proliferation of cardiac progenitor cells. It is also proposed to down-regulate pathological fibroblast maturation, potentially reducing scar formation and fibrotic remodeling after ischemic injury — though no human mechanistic studies confirm this pathway.
Personalized Peptides provides DNA-driven peptide recommendations — we are not a compounding pharmacy, peptide synthesis company, or clinical provider.
Did you know
Cardiogen doesn't just repair the heart — in rat sarcoma models it appeared to selectively trigger cancer cell death in tumors while simultaneously protecting cardiac cells from dying, suggesting a mechanism that 'reads' cell health context before deciding whether to save or destroy.
Preclinical Data
No human PK studies available.
Russian cytomedicine — no independent PK data
Class
Tetrapeptide cardiac bioregulator (Khavinson cytomedicine)
Route
SC / Oral
Mol. Weight
416.4 Da
What we don't know
No PK studies in any species. Tetrapeptide size suggests rapid absorption and clearance. The gene-switching mechanism, if operative, would produce effects that outlast plasma PK by days to weeks — making conventional PK characterisation less relevant to dosing strategy.
Why this dosing protocol
Standard bioregulator protocol: 5-10mg SC daily for 10-30 days, repeated 2-3× per year. Used in Russian cardiology for post-MI recovery and age-related cardiac decline. Often combined with other Khavinson peptides in comprehensive longevity protocols.
Empirical protocol: 5-10mg SC daily × 10-30 days
Safety notes
- Russian-only data
- Cardiac safety in Western populations unknown
Pharmacokinetic data shown for educational context. All parameters are inferred or empirically derived — no formal human PK studies exist for this compound. Individual response varies. Not a substitute for clinical dosing guidance.
Benefits
What it does.
In preclinical rat studies, Cardiogen reduced cardiomyocyte apoptosis by down-regulating p53 expression in myocardial tissue
May promote cardiac progenitor cell proliferation and support myocardial regeneration after injury, based on rat cardiac tissue studies (effects seen in both young and old animals)
Reported in Russian clinical literature to support healthy blood pressure, with 5–15 mmHg systolic reductions observed during long-term clinical use — the underlying mechanism has not been independently confirmed
May help reduce inflammatory signaling and oxidative stress in cardiac tissue, consistent with the broader Khavinson bioregulator model, though specific biomarker data (CRP, IL-6) for Cardiogen has not been independently verified
May help slow age-related cardiac decline by supporting gene expression patterns associated with cardiomyocyte survival, based on preclinical studies showing effects in both young and old rat cardiac tissue
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
What this does not mean
Cardiogen is a research chemical. The information on this page is educational and does not constitute medical advice, diagnosis, or treatment. Cardiogen is not FDA-approved for treating cardiac conditions, blood pressure, or any other use, and has no independent Western clinical or pharmacokinetic data — available evidence comes primarily from preclinical rat studies and Russian clinical literature. This page does not recommend, endorse, or prescribe any compound for human use. Always consult a qualified healthcare provider before making health decisions. Personalized Peptides provides DNA-driven educational context and test interpretation — not clinical protocols or pharmaceutical recommendations.
Cardiogen demonstrated significant stimulating effect on cardiomyocyte proliferation in both young and old rat cardiac tissue; immunohistochemical analysis confirmed decreased p53 expression, indicating inhibition of apoptosis in myocardial tissue
SOURCE · St. Petersburg Institute of Bioregulation and Gerontology; reported in Core Peptides / Atlas of Science review of Khavinson laboratory research
Cardiogen showed dose-dependent inhibition of M-1 sarcoma growth in rat models through development of hemorrhagic necrosis and stimulation of tumor cell apoptosis — suggesting selective pro-survival action in cardiac cells vs. pro-apoptotic action in tumor cells
SOURCE · Levdik & Knyazkin, Russian Academy of Medical Sciences; cited in biotechpeptides.com (2024)
Clinical use over several decades in Russia showed improvements in ischemic heart disease symptoms, heart failure markers, blood pressure (5–15 mmHg systolic reduction), and angina frequency with minimal adverse effects
SOURCE · SeekPeptides review of Russian clinical literature; Revolution Health & Wellness clinical summary (2024)
Protocol
How to use it.
Dosing
Injectable: 5–20 mcg subcutaneously per day, or every other day, as used in research protocols. Oral capsule forms (where available): 20–80 mg/day divided into 1–2 doses with meals. Protocols are typically 10–30 day cycles.
Cycle
Standard cycle: 10–14 days on, repeat 2–4 times per year for maintenance or preventive use. Post-cardiac-event protocols may extend to 20–30 days. Allow 1–3 months between cycles.
Contraindications
When to skip it.
No significant toxicity reported in available research. Use with caution in patients on anticoagulants or anti-hypertensives (additive effects possible). Not FDA-approved; research-grade only. Avoid in pregnancy (insufficient data). Consult physician before combining with cardiac medications.
Always cleared with your concierge before protocol start.
Regulatory Context
FDA compounding status.
| FDA Status | Risk Level | Compounding | Key Date |
|---|---|---|---|
| No specific FDA action | 🟢 Stable | Gray zone — no specific enforcement | No pending dates |
Heart-specific cytoprotective peptide. Not on any FDA Category 1/2/3 lists. No pending PCAC review. No known enforcement actions.
Source: FDA Federal Register, PCAC agendas, industry analyses. Educational context only — not legal advice. Review after July 23-24, 2026 PCAC meeting.
Pricing
What it costs.
Indicative range for Cardiogen, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Includes vial and reconstitution guidance
- 03Concierge supplier match included with every protocol
See Cardiogen pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $120–$180 USD